Safety and Clinical Outcome of Experimental Challenge of Human Volunteers with Plasmodium falciparum–Infected Mosquitoes: An Update
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Challenge of volunteers by the bites of membrane-fed anopheline mosquitoes infected with Plasmodium falciparum was reported in 1986. In 1997, an analysis of experience with 118 volunteers indicated that mosquito inoculation of P. falciparum could be a safe, well-tolerated, reproducible, and efficient method of challenge. METHODS: We reviewed the records of 47 volunteers challenged at our institution with the NF54 isolate of P. falciparum between 1998 and 2002. We also reviewed data from 17 published studies of experimental challenge conducted since 1996. RESULTS: At our institution, the time to onset of first symptoms (incubation period) was 8.9 days, and the time to first detectable parasitemia on blood smear (prepatent period) was 10.5 days. All volunteers became symptomatic. Most symptoms were mild to moderate, although 21% of volunteers had at least 1 severe symptom. None developed complicated or severe malaria, and all were cured. Laboratory assessments demonstrated modest, short-term abnormalities typical of malaria. Review of 17 published studies demonstrated that an additional 367 volunteers received experimental challenge safely with similar outcomes. CONCLUSIONS: In total, data from 532 volunteers demonstrate that experimental challenge is safe and results in predictable incubation and prepatent periods. Our findings support the continued use of this method for testing efficacy of vaccines and drugs against P. falciparum.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stoute, J. A., Slaoui, M., Heppner, D. G., Momin, P., Kester, K. E., Desmons, P., Wellde, B. T., Garçon, N., Krzych, U., Marchand, M., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199701093360202 · Cited by 870 · cited 3×
“WRAIR [17] RTS,S 13/22 6/6 3D7 Chloroquine Range, 11-19 Range, 11–13 Smear 5”
Influential
Cited by
Kisalu, N. K., Idris, A. H., Weidle, C., Flores-Garcia, Y., Flynn, B. J., Sack, B. K., Murphy, S., Schön, A., Freire, E., Francica, J. R., et al. (2018) · Nature Medicine · doi:10.1038/nm.4512 · Cited by 293
Self-citationExperimental human challenge infections can accelerate clinical malaria vaccine development
Sauerwein, R. W., Roestenberg, M., & Moorthy, V. S. (2011) · Nature Reviews Immunology · doi:10.1038/nri2902 · Cited by 267
De Mast, Q., Van Dongen‐Lases, E. C., Swinkels, D. W., Nieman, A., Roestenberg, M., Druilhe, P., Arens, T. A., Luty, A. J., Hermsen, C. C., Sauerwein, R. W., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07664.x · Cited by 74
“By use of a stringent protocol, experimental human malarial infections have been proven to be reproducible and generally well tolerated (Verhage et al, 2005; Epstein et al, 2007).”
BackgroundMapping multiple components of malaria risk for improved targeting of elimination interventions
Cohen, J. M., Le Menach, A., Pothin, E., Eisele, T. P., Gething, P. W., Eckhoff, P. A., Moonen, B., Schapira, A., & Smith, D. L. (2017) · Malaria Journal · doi:10.1186/s12936-017-2106-3 · Cited by 68
“As symptoms typically manifest around the tenth day of infection in non-immune individuals, prompt, effective treatment can greatly reduce the duration of infectivity of clinical cases [60].”
BackgroundBorrmann, S., Peto, T., Snow, R. W., Gutteridge, W., & White, N. J. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050227 · Cited by 15
“As many drugs have no effects on pre-erythrocytic (liver stage) development, new blood stage infections may become patent as early as one week after blood concentrations of the antimalarial drug fall below the minimum inhibitory concentration (MIC) [24].”
BackgroundInfluential
Metadata
- Authors
- Epstein, J. E., Rao, S., Williams, F., Freilich, D., Luke, T., Sedegah, M., Vega, P. D. L., Sacci, J., Richie, T. L., & Hoffman, S. L.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-07
- Volume
- 196
- Issue
- 1
- Pages
- 145-154
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2082324603
- Cited by
- 124
- References
- 1
- FWCI
- 8.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.